【Product for Licensing】 A BIC Vaccine Adjuvant for Human and Animal Vaccines

Project ID：BP-20240705-OR-69

Product Brief Summary

• Product Name: A potentially best-in-class (BIC) innate immune receptor TLR agonist
• Modality: Recombinant vaccines
• Target: TLR9
• MOA: Itself or in combination with other commercial adjuvants greatly enhances the Ag-specific titer, especially cell immunity antibody (mouse IgG2a)
• Therapeutic Area: Shingles vaccines (IM)/Flu vaccines (Intranasal)
• Current Stage: IND preparation
• Rights Available: China/Global Right
• Collaboration Mode: License out

Advantages

• Active in multiple species including human, swine, mouse and chicken
• As a human vaccine adjuvant, the product is significantly better than existing and approved adjuvants in enhancing both mucosal and cell-mediated immunities in mouse studies
• Itself or in combination with other commercial adjuvants greatly enhances the Ag-specific titer especially
• cell immunity antibody (IgG2a)
• Shows significantly enhanced protective immunity in several Swine vaccines

Superior Activities in Enhancing Cellular and Humoral Immunities in Mouse Models

• In C56/B7 mice studies, The adjuvanted recombinant shingles vaccines showed significantly better Ig2a/IgG1 (representing cellular immunity) than the GSK vaccine Shingrix
• The adjuvanted shingles vaccines elicited significantly higher gE specific proportions of IFN-γ, IL-2 and CD40-L expressing CD4 T cells than those induced by Shingrix or CPG-1018 adjuvanted recombinant shingles vaccine

Current Progresses

With collaborators, the candidate is in two ongoing vaccine development projects for IND preparation

GMP-grade adjuvant for clinical vaccine development can be provided

Contact

• If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!